This committee is responsible for overall decision making related to the trial.
Zoe McQuilten - Chair
Steve Webb
David Paterson
George Heriot
Jason Roberts
Julie Marsh
Matthew Scarborough
Steven Tong
David Lye
Genevieve Walls
Susan Morpeth
Tom Boyles
Marc Bonten
Marjolein Hesgens
Joshua Davis
Nick Daneman
Dafna Yahav
Anna Goodman
Matthew Cheng
Catherine Cosgrove
Cesar Arias
Lynda Whiteway
Asha Bowen
Sebastiaan van Hal
Todd Lee
Roger Lewis
Owen Robinson
Hiroki Saito
David Huang - Chair, DSMC
Anna McGlothlin - Chair; AT
Jason Connor - DSMC
Michael Dymock -AT
Robert Mahar - AT
Thomas Holland - DSMC
Joanne Langley - DSMC
Erin McCreary - DSMC
This subcommittee is responsible for considering all statistical aspects for the trial, and writing the statistical appendices, simulations appendix, and the statistical analysis plan.
Julie Marsh - Chair
Josh Davis
Rebecca Turner
Scott Berry
Hannah Carter
Roger Lewis
Todd Lee
Alistair McLean
Steven Tong
Jonas Tverring
Hannah Carter
Steve Webb
Thomas Lumley
Tom Snelling
The group will write the domain specific appendix for the PSSA and MSSA backbone domains, and will lead the analysis and reporting of the results from these domains.
Todd Lee - Chair
Andrew Henderson
Miquel Ekkelenkamp
Brendan McMullan
Genevieve McKew
Ilse Kouijzer
Steven Tong
Nesrin Ghanem-Zoubi
Nynke de Jager
Josh Davis
Anna Goodman
Achim Kaasch
The group will write the domain specific appendix for the MRSA backbone domain, and will lead the analysis and reporting of the results from this domain.
David Lye - Chair
Josh Davis
Phil Britton
Anna Goodman
Matthew O'Sullivan
Susan Morpeth
Neta Petersiel
Steven Tong
Hong Foo
Jon Underwood
Jennie Johnstone
Shirin Kalimuddin
Todd Lee
The group will write the domain specific appendix for the adjunctive clindamycin domain, and will lead the analysis and reporting of the results from this domain.
Asha Bowen - Chair
Ravindra Dotel
Steven Tong
Lesley Voss
Michael Marks
Jonas Tverring
Josh Davis
Derek MacFadden
Anna Goodman
Neta Petersiel
Simon Smith
The group will write the domain specific appendix for the early oral switch domain, and will lead the analysis and reporting of the results from this domain.
Genevieve Walls - Co-chair
Anna Goodman - Co-chair
Susan Morpeth
Anita Campbell
Achim Kaasch
Todd Lee
Shirin Kalimuddin
Dafna Yahav
Archana Sud
Steven Tong
Stephen Guy
Amy Legg
Jaap Ten Oever
Matthew Cheng
Max Bloomfield
Michael Marks
Marjolein Hensgens
The group will write the domain specific appendix for the PET/CT domain, and will lead the analysis and reporting of the results from this domain.
Anna Goodman - Co-Chair
Michal Paul - Co-Chair
George Heriot
Abby Douglas
Jaap Ten Oever
Joshua Davis
Martin Llewelyn
Nesrin Ghanem-Zoubi
Olga Kagana
Marjolein Hensgens
Neta Petersiel
Steven Tong
Andrew Scott
Richard De Abreu Lourenco
Matthew Cheng
Roslyn Francis
Gary Cook
Jennifer Bostock
Ilse Kouijzer
Todd Lee
This group will plan and oversee the pharmacokinetic and pharmacodynamic aspects of the trial, review and recommend treatment dose and frequency, and plan relevant sub studies for SNAP.
Jason Roberts - Chair
Marc Scheetz
Debbie Marriott
Max Bloomfield
Amanda Gwee
Eliza Milliken
Nynke de Jager
Amy Legg
Steven Tong
Roger Brüggemann
Andrea Kwa
Josh Davis
Anne Martson
This group will plan and oversee the microbiological aspects of the trial.
Sebastiaan Van Hal - Chair
Ben Howden
Susan Morpeth
Neil Stone
Eugene Athan
Owen Robinson
Matthew Cheng
Jennifer Grant
Yen-Ee Tan
Steven Tong
Stefano Guilieri
Geoff Coombs
Rispah Chomba
Andrew Henderson
Dan Gregson
Ka Lip Chew
Diane Daniel
Responsible for the registry appendix to the core protocol and managing a patient registry. All patients with S. aureus bloodstream infections at participating SNAP sites will be invited to join this registry, including those who decline to participate in the SNAP trial.
This group will write the pregnancy and the paediatric appendices to the core protocol and will consider how to incorporate paediatric and pregnancy-specific aspects into the trial.
Asha Bowen - Chair
Kevin Schwartz
Oded Scheuerman
Lesley Voss
Michael Meyer
Michael Stark
Rachel Webb
Anita Campbell
Amanda Gwee
Clare Nourse
Tobias Strunk
Josh Davis
Steven Tong
Srinivas Murthy
Brendan McMullan
Erica Hardy
Jesse Papenburg
Jia Hui Li
Emma Best
Isabelle Malhamé
Phil Britton
James Hatcher
Brett Manley
Anna Goodman
This group will write the PWID appendix for the trial, and will lead the analysis and reporting of the results from this group of patients.
Gail Matthews - Co-Chair
Andrew Stewardson - Co-Chair
Carly Botheras
Terry Wuerz
Archana Sud
Adrian Dunlop
Steven Tong
Marianne Martinello
Martin Llewelyn
Eugene Athan
Josh Davis
This group will focus on the IE/CDI aspects involved in the SNAP Trial, and will lead the development of sub studies relating to this cohort of participants.
Eugene Athan - Chair
Todd Lee
William Kong
George Heriot
Gareth Wynn
Steven Tong
John Sedgwick
Joshua Davis
Mohammed Rizwan
This group will write the Health Economics appendix for the trial, and will lead the analysis and reporting of the health economic results from the trial.
Hannah Carter - Chair
Richard De Abreu Lourenco
Sean Ong
Steven Tong
Anna Goodman
Joshua Davis
Dina Jankovic
Marta Soares
Lisa Higgins
Responsible for considering the aspects specific to Australia in the planning and running of the trial, including advising the GTSC on site selection and local variations of interventions and usual practice.
Owen Robinson - Chair, WA
Steven Tong - SNAP Trial CI
Josh Davis - SNAP Trial CI
Jane Davies - NT
Andrew Henderson - QLD
Katie Flanagan - TAS
Ben Rogers - VIC
Nick Anagnostou - SA
Heather Wilson - ACT
Gillian Woods - WA
Matthew O'Sullivan - NSW
Clare Nourse - QLD
Responsible for providing advice and inform decisions from a community perspective to give a voice to Aboriginal community members in the development, conduct and oversight of the trial.
Gillian Woods - Chair; WA
Kristy Crooks - NSW
Mark Mayo - NSW
Developed to ensure that all elements of the trial are carried out with consumer engagement to support improving lives of those who are affected by SAB.
Responsible for considering the aspects specific to New Zealand in the planning and running of the trial, including advising the GTSC on site selection and local variations of interventions and usual practice.
Genevieve Walls - Chair
Susan Morpeth
Max Bloomfield
Kate Grimwade
Colin McArthur
Diana McNeill
Sarah Metcalf
Steven Tong - SNAP Trial CI
Viliame Tutone
Lesley Voss
Rachel Webb
Responsible for considering the aspects specific to Canada in the planning and running of the trial, including advising the GTSC on site selection and local variations of interventions and usual practice.
Nick Daneman - Chair, ON
Joshua Davis - SNAP Trial CI Matthew Cheng - QC
Todd Lee - QC
Peter Daley - NL
Jennie Johnstone - ON
Terry Wuerz - MB
Dan Gregson - AB
Jennifer Grant - BC
Responsible for considering the aspects specific to Israel in the planning and running of the trial, including advising the GTSC on site selection and local variations of interventions and usual practice.
Responsible for considering the aspects specific to Singapore in the planning and running of the trial, including advising the GTSC on site selection and local variations of interventions and usual practice.
David Lye - Chair
Steven Tong - SNAP Trial CI
Ka Lip Chew
Shirin Kalimuddin
Partha De
Yen-Ee Tan
Sophia Archuleta
Russel Lee
Responsible for considering the aspects specific to the UK in the planning and running of the trial, including advising the GTSC on site selection and local variations of interventions and usual practice.
Anna Goodman - Chair
James Hatcher
Jennifer Bostock - Consumer Rep
Jon Underwood
Marta Soares
Martin Llewelyn
Matthew Scarborough
Michael Marks
Neil Stone
Rebecca Turner
Sarah Pett
Steven Tong - SNAP Trial CI
Responsible for considering the aspects specific to Europe in the planning and running of the trial, including advising the GTSC on site selection and local variations of interventions and usual practice.
Responsible for considering the aspects specific to South Africa in the planning and running of the trial, including advising the GTSC on site selection and local variations of interventions and usual practice.
Learn more about why we’re studying treatments for S. aureus bloodstream infections in the SNAP trial.
Learn more about why we’re studying treatments for S. aureus bloodstream infections in the SNAP trial.
